About Celmatix
Celmatix is a company based in New York (United States) founded in 2009. Celmatix has raised $24.89 million across 7 funding rounds from investors including Regional Economic Development Councils and Topspin Consumer Partners. The company has 27 employees as of December 31, 2022. Celmatix offers products and services including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor. Celmatix operates in a competitive market with competitors including Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
- Headquarter New York, United States
- Employees 27 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Celmatix Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.89 M (USD)
in 7 rounds
-
Latest Funding Round
$4.5 M (USD), Series C
Dec 18, 2017
- Investors
-
Employee Count
27
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Celmatix
Celmatix offers a comprehensive portfolio of products and services, including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.
Targets ovarian aging and related health issues in women.
Advances infertility therapies through targeted hormone stimulation.
Addresses inflammation and pain in women's health conditions.
People of Celmatix
Unlock access to complete
Unlock access to complete
Funding Insights of Celmatix
Celmatix has successfully raised a total of $24.89M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $4.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Celmatix
Celmatix has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Regional Economic Development Councils and Topspin Consumer Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Celmatix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celmatix
Investment portfolio details for Celmatix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celmatix
Detailed financials for Celmatix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celmatix Comparisons
Peer comparison for Celmatix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celmatix
Celmatix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
|
| Locked | Locked | Locked |
Provider of biochemical/genetic tests to detect mutations and rare diseases
|
|
| Locked | Locked | Locked |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
|
| Locked | Locked | Locked |
High-throughput gene sequencing platform is developed for clinical diagnostics.
|
Detailed competitors of Celmatix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celmatix
Complete news archive for Celmatix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celmatix
Celmatix was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Celmatix is headquartered in New York, United States. It is registered at New York, New York, United States.
Celmatix is a funded company, having raised a total of $24.89M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Celmatix is 27.
Celmatix focuses on womens health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a cloud- based analytics platform for optimizing a womans fertility by calculating the personal likelihood of success using various fertility treatment options, tailored to a patients clinical metrics. In addition, the company offers Fertilome, an NGS assay that enables women to evaluate present and future fertility potential. Fertilome analyzes 49 different variants in 32 genes, and is specifically aimed at women who plan to freeze their eggs, have children after the age of 35, or have risk factors that affect fertility such as PCOS, depleted ovarian reserve, endometriosis or other endocrine disorders.
Celmatix's top competitors include Fulgent Genetics, Centogene and Myriad Genetics.
Celmatix offers AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.
Celmatix has 2 investors. Key investors include Regional Economic Development Councils, and Topspin Consumer Partners.